Three new drugs increase options for CML patients

submitted by: mdanderson

Jorge Cortes, M.D., discusses how ponatinib, bosutinib and omacetaxine, approved by the FDA recently, can help chronic myeloid leukemia patients.

Facts about myelodysplastic syndrome

submitted by: mdanderson
Around 15,000 people in the United States are diagnosed each year with myelodysplastic syndrome (MDS). MDS occurs when the bone marrow does not properly produce one or more of the following: red blood cells, white blood cells and/or platelets. In the past it was thought MDS was only deadly when it developed into acute myelogenous leukemia (AML), but current research shows MDS can be fatal without reaching the stage of AML. Guillermo Garcia-Manero, M.D., professor in Leukemia, explains the...

Acute myeloid leukemia (AML) - a life threatening cancer

submitted by: mdanderson

Acute myeloid leukemia (AML) occurs when too many immature blood cells are produced by the bone marrow. Anemia, infection and bleeding may result and become life threatening. Guillermo Garcia-Manero, M.D., professor in Leukemia at MD Anderson Cancer Center, explains the symptoms, diagnosis and treatment of Acute myeloid leukemia.

Childhood Leukemia: Most Common Childhood Cancer

submitted by: mdanderson

Childhood leukemia is the most common childhood cancer with more than 3,500 children in the U.S. diagnosed each year. Patrick Zweidler-McKay, M.D., Ph.D., Assistant Professor at The University of Texas MD Anderson Cancer Center Children’s Cancer Hospital, talks about symptoms, diagnoses and treatment of this blood disease. Zweidler-McKay also discusses health problems that may occur decades after treatment and encourages long term follow-up doctor visits.

Treating Leukemia - Dr. Stefan Faderl

submitted by: mdanderson

Dr. Stefan Faderl discusses the basics of leukemia, his philosophy on treating the disease and MD Anderson's multicultural approach to care. He recognizes that leukemia patients require quick intervention and treatment. Learn more about Leukemia treatment at MD Anderson cancer center http://bit.ly/kHCp1G

Treatment Could Provide Relief for Leukemia Patients

submitted by: mdanderson
At least 40% of leukemia patients seen at MD Anderson Cancer Center in Houston, experience pneumonia in their initial treatments. Scott Evans, M.D., assistant professor in Pulmonary Medicine, Evans and his colleagues have identified a combination of two small molecules that stimulate the lungs to become resistant to infection. They're goal is to use this combination to prevent pneumonia in patients with acute leukemia. Evans describes the research that's being done. http://bit.ly/iMGN4b

Identification and Regulation of c-Myb Target Genes in MCF-7 cells.

submitted by: aquintan
BACKGROUND: The c-Myb transcription factor regulates differentiation and proliferation in hematopoietic cells, stem cells and epithelial cells. Although oncogenic versions of c-Myb were first associated with leukemias, over expression or rearrangement of the c-myb gene is common in several types of solid tumors, including breast cancers. Expression of the c-myb gene in human breast cancer cells is dependent on estrogen stimulation, but little is known about the activities of the c-Myb...
Authors: Anita m. Quintana, Fan Liu, John p. O'rourke, Scott a. Ness

The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers

submitted by: BernardFriedenson
Background The present study was designed to test the hypothesis that inactivation of virtually any component within the pathway containing the BRCA1 and BRCA2 proteins would increase the risks for lymphomas and leukemias. In people who do not have BRCA1 or BRCA2 gene mutations, the encoded proteins prevent breast/ovarian cancer. However BRCA1 and BRCA2 proteins have multiple functions including participating in a pathway that mediates repair of DNA double strand breaks by error-free...
Authors: Bernard Friedenson